Table 4.
Association of independent factors with metabolic syndrome among HIV infected patients using ART at Hawassa, southern Ethiopia
| Explanatory variable | Metabolic syndrome by using IDF criteria | Metabolic syndrome by using NCEP-ATP criteria | ||||
|---|---|---|---|---|---|---|
| Presence of MetS = N (%) | COR (95 % CI) | AOR (95 % CI) | Presence of MetS = N (%) | COR (95 % CI) | AOR (95 % CI) | |
| BMI (kg/m2) | ||||||
| ≤25 | 30 (16.2) | 1.00 | 1.00 | 21 (11.3) | 1.00 | 1.00 |
| >25 | 15 (8.1) | 3.0 (1.3–6.5) | 3.8 (1.5–9.8) | 12 (6.5) | 3.2 (1.4–7.4) | 3.4 (1.3–9.2) |
| p value | 0.006 | 0.005 | 0.006 | 0.01 | ||
| Gender | ||||||
| Male | 6 (3.2) | 1.00 | 1.00 | 12 (6.5) | 1.00 | 1.00 |
| Female | 39 (21.1) | 5.1 (2.0–12.9) | 7.9 (2.6–24.1) | 21 (11.3) | 1.0 (0.47–2.3) | 1.5 (0.24–1.8) |
| p value | <0.0001 | <0.0001 | 0.19 | 0.43 | ||
| Age (years) | ||||||
| ≤40 | 41 (22.1) | 1.00 | 1.00 | 25 (13.5) | 1.00 | 1.00 |
| >40 | 4 (2.1) | 0.66 (0.21–2.0) | 2.0 (0.45–9.5) | 8 (4.3) | 3.1 (1.2–8.3) | 3.8 (1.0–13.7) |
| p value | 0.21 | 0.35 | 0.02 | 0.04 | ||
| ART use (months) | ||||||
| ≤48 | 22 (11.9) | 1.00 | 1.00 | 20 (10.8) | 1.00 | 1.00 |
| >48 | 23 (12.4) | 1.8 (0.95–3.7) | 2.3 (1.0–5.4) | 13 (7.0) | 0.99 (0.46–2.1) | 0.8 (0.32–1.9) |
| p value | 0.07 | 0.04 | 0.20 | 0.33 | ||
| Cigarette | ||||||
| Never smoke | 43 (23.2) | 1.00 | 1.00 | 28 (15.1) | 1.00 | 1.00 |
| Still smoking | 2 (1.1) | 0.26 (0.06–1.1) | 0.17 (0.03–1.0) | 5 (2.7) | 1.3 (0.45–3.9) | 0.47 (0.10–2.1) |
| p value | 0.08 | 0.05 | 0.18 | 0.33 | ||
| Education | ||||||
| Illiterate | 1 (0.5) | 1.00 | 1.00 | 3 (1.6) | 1.00 | 1.00 |
| Primary | 22 (11.9) | 6.7 (0.8–53.3) | 10.1 (1.1–94) | 15 (8.1) | 1.2 (0.31–4.7) | 0.85 (0.17–4.3) |
| p value | 0.07 | 0.04 | 0.16 | 0.24 | ||
| Secondary and above | 22 (11.9) | 6.2 (0.79–49.9) | 10.9 (1.1–104) | 15 (8.1) | 1.1 (0.3–4.4) | 1.1 (0.45–2.8) |
| p value | 0.08 | 0.04 | 0.21 | 0.37 | ||
ART antiretroviral therapy, COR crude odds ratio, AOR adjusted odds ratio, CI confidence interval, BMI body mass index, EFV Efavirenz, NVP Nevirapine, NNRTI non nucleoside reverse transcriptase inhibitors